<DOC>
	<DOCNO>NCT01238835</DOCNO>
	<brief_summary>A single arm , prospective multicenter non-randomized confirmatory clinical trial evaluate Edwards SAPIEN XT™ transcatheter heart valve ( model 9300TFX ; `` study valve '' ) , next generation Ascendra™ transapical delivery system , crimper accessory .</brief_summary>
	<brief_title>Placement Aortic Balloon Expandable Transcatheter Valves Trial ( TransApical )</brief_title>
	<detailed_description>Purpose : The purpose trial evaluate acute safety effectiveness SAPIEN XT™ study valve next generation Ascendra™ delivery component . Follow-up Intervals : Subject data collection include clinical information baseline index procedure . Subjects undergo clinical follow-up discharge , 30 day , 6 month annually 5 year .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Inclusion : 1 . EuroSCORE ≥ 15 % 2 . Severe senile degenerative aortic valve stenosis 3 . Symptomatic aortic valve stenosis 4 . Informed consent 5 . Compliance Exclusion : 1 . Logistic Euroscore &gt; 40 % 2 . Evidence acute myocardial infarction 3 . Congenital unicuspid congenital bicuspid valve/ noncalcified 4 . Mixed aortic valve disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sapien XT Valve</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Therapy</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transcatheter</keyword>
</DOC>